Loading organizations...
Loading organizations...
Global immunology company focused on autoimmune diseases and cancer.
argenx was founded by Tim Van Hauwermeiren (Founder and CEO).
argenx has raised $93.6M in total across 5 funding rounds.
argenx was founded by Tim Van Hauwermeiren (Founder and CEO).
argenx has raised $93.6M in total across 5 funding rounds.
argenx's investors include Aquilo Capital, Burrage Capital, Dafna Capital, MPM Capital, Perceptive Advisors, Chris De Jonghe, Michael B. Sheffery, Isabelle de Cremoux, BioGeneration Ventures, Credit Agricole Private Equity, Erasmus Biomedical Fund, Forbion.
Key people at argenx.
argenx has raised $93.6M across 5 funding rounds. Most recently, it raised $34.0M Other Equity in June 2016.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 16, 2026 | Unnatural Products | $45.0M Series B | Nicholas Shekerdemian | Droia Ventures, First Spark Ventures, Merck |
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 3, 2016 | $34.0M Other Equity | Aquilo Capital, Burrage Capital, Dafna Capital, MPM Capital, Perceptive Advisors | |
| Nov 6, 2013 | $6.8M Series B Extension | Chris De Jonghe | |
| Dec 1, 2011 | $37.1M Series B | Michael B. Sheffery, Isabelle de Cremoux | BioGeneration Ventures, Credit Agricole Private Equity, Erasmus Biomedical Fund, Forbion, LSP, Thuja Capital, VIB |
| Nov 3, 2009 | $1.9M Grant | Institute for the Promotion of Innovation by Science and Technology in Flanders | |
| Sep 10, 2009 | $13.8M Series A | Forbion, LSP | BioGeneration Ventures, Erasmus MC O&O Holdings, KBC, Thuja Capital |
